* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download N receptors
Pharmacogenomics wikipedia , lookup
Discovery and development of TRPV1 antagonists wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Prescription costs wikipedia , lookup
Pharmacognosy wikipedia , lookup
Discovery and development of beta-blockers wikipedia , lookup
Toxicodynamics wikipedia , lookup
Discovery and development of antiandrogens wikipedia , lookup
NMDA receptor wikipedia , lookup
5-HT2C receptor agonist wikipedia , lookup
Drug interaction wikipedia , lookup
5-HT3 antagonist wikipedia , lookup
Discovery and development of angiotensin receptor blockers wikipedia , lookup
Cannabinoid receptor antagonist wikipedia , lookup
NK1 receptor antagonist wikipedia , lookup
Neuropharmacology wikipedia , lookup
Psychopharmacology wikipedia , lookup
Pharmacology of efferent nervous system Shi-Hong Zhang (张世红), PhD Dept. of Pharmacology, School of Medicine, Zhejiang University [email protected] Nervous System Peripheral Nervous System (PNS) Central Nervous System (CNS) Organization of the nervous system Peripheral Nervous System (PNS) Efferent Division Autonomic System (ANS) Afferent Division Somatic System Parasympathetic Sympathetic Enteric The Enteric Nervous System (+SNS/PSNS) Sympathetic stimulation causes: • • • • • • stimulates heartbeat raises blood pressure dilates the pupils dilates the trachea and bronchi stimulates the conversion of liver glycogen into glucose shunts blood away from the skin and viscera to the skeletal muscles, brain, and heart • inhibits peristalsis (蠕动) in the gastrointestinal (GI) tract • inhibits contraction of the bladder and rectum Parasympathetic stimulation causes: • slowing down of the heartbeat • lowering of blood pressure • constriction of the pupils • increased blood flow to the skin and viscera • peristalsis of the GI tract Nervous System Peripheral Nervous System (PNS) Efferent Division Central Drugs that produce their Nervous System (CNS) primary therapeutic effect by Afferent Division mimicking or altering the functions of autonomic nervous system are called Autonomic System (ANS) Somatic System autonomic drugs. Parasympathetic Sympathetic Enteric Organization of the nervous system Neurotransmitters • Synthesis • Storage • Release • Degradation Receptors • Activation • Blockade Drug actions and classification (1) Mimetics - direct-acting: receptor agonists - indirect-acting: increasing amounts and/or effects of transmitters (2) Antagonists - direct-acting: receptor antagonists - indirect-acting: decreasing amounts and/or effects of transmitters Autonomic Pharmacology • Cholinergic Pharmacology • Adrenergic Pharmacology CASE STUDY • In mid-afternoon, a coworker brings 43-year-old JM to the emergency department because he is unable to continue picking vegetables. His gait is unsteady and he walks with support from his colleague. JM has difficulty speaking and swallowing, his vision is blurred, and his eyes are filled with tears. His coworker notes that JM was working in a field that had been sprayed early in the morning with a material that had the odor of sulfur. Within 3 hours after starting his work, JM complained of tightness in his chest that made breathing difficult, and he called for help before becoming disoriented. Cholinergic Terminal • Choline Uptake→ • ACh Synthesis Choline + AcCoA → ACh ChAT • ACh Storage • ACh Release • ACh Effects - Postsynaptic - Presynaptic • ACh inactivation ACh → Choline + Acetate AChE Acetylcholine Release Regulation - by autoreceptors ACh acting on presynaptic m2-cholinergic receptors - by heteroreceptors NE acting on presynaptic alpha2-adrenergic receptors - by metabolism (extraneuronal) ACh inactivation Cholinesterases Acetylcholinesterase is located at cholinergic synapses and in erythrocytes (does not hydrolyze succinylcholine) Pseudocholinesterase (synonyms: plasmacholinesterase or butyrylcholinesterase丁酰胆碱脂酶 ) occurs mainly in plasma, liver and in glia (hydrolyzes succinylcholine) Cholinergic Receptors • Muscarinic receptors (M receptors) M1, 3, 5 (smooth muscles); M2, 4(heart) G-protein Coupled End Organs • Nicotinic receptors (N receptors) NN (N1) receptors; NM(N2 ) receptors Ligand-gated Ion Channels NMJ & Ganglia M receptors : G-protein Coupled Muscarinic Receptor Signaling Pathways M receptors: • Depression of the heart (heart rate, conduction) • Contraction of smooth muscles (sensitive: GI tract, bronchial, urinary bladder; insensitive: uterine, blood vascular) • Exocrine glands (sensitive: sweat, tear, salivary; insensitive: GI tract); • Eye (contraction of sphincter muscle of iris: miosis; contraction of ciliary muscle睫状肌: contraction for near vision) Cholinergic Vasodilation • The response of an isolated blood vessel to ACh depends on whether the endothelium is intact (unrubbed) or missing • When the endothelium is present, ACh causes smooth muscle relaxation by stimulating the production of nitric oxide (NO) in the endothelium • In the absence of the endothelium, a small amount of vasoconstriction is observed N receptors • NN receptors( N1 receptors ) - Sympathetic and parasympathetic ganglia - Adrenal medulla • NM receptors (N2 receptors ) - The Neuromuscular Junction (NMJ) (Contraction of skeletal muscles) N receptors : Ligand-gated Ion Channels • At the NMJ, N receptors pentameric with four types of subunits, two a subunits bind ACh for ligand gating • All other nAChRs, including those at the peripheral ganglia, have 2 a’s and 3 b’s Ganglionic Neurotransmission N = Nicotinic AChR M = Muscarinic AChR EPSP = Excitatory Postsynaptic Potential IPSP = Inhibitory Postsynaptic Potential The Neuromuscular Junction (NMJ) A B Myasthenia Gravis • This means “serious disorder the NMJ” • This is an autoimmune disease • Antibodies against the a subunit of the nAChR • The ability of ACh to activate the nAChRs is blocked by the antibodies • As many autoimmune diseases, stress can make the symptoms worse • Treatment is to potentiate cholinergic signaling and to remove the antibodies (blood dialysis) Drug classification 1. Cholinomimetics (1) Direct-acting drugs: Cholinoceptor agonists M, N receptor agonists: acetylcholine M receptor agonists: pilocarpine N receptor agonists: nicotine (2) Indirect-acting drugs: Cholinesterase inhibitors (Anticholinesterases) Reversible: neostigmine新斯的明 Irreversible: organophosphates 有机磷酸酯类 Cholinesterase reactivators: pralidoxime iodide 碘解磷定 Drug classification 2 Cholinergic antagonists (1) Cholinoceptor antagonists M cholinoceptor antagonists atropine (Antimuscarinic drugs) N cholinoceptor antagonists NN cholinoceptor antagonists: mecamylamine (Ganglionic blocking drugs, rarely used) NM cholinoceptor antagonists: succinylcholine (Neuromuscular blocking drugs ) (2) Botulinum Toxin (Botox, blocks ACh release) Cholinomimetics Direct-acting drugs Ach derivatives (胆碱酯类) Natural muscarinic agonists (生物碱类M 受体激动剂) Nicotinic receptor agonists (N受体激动剂) ACh Derivatives Bond cleaved by AChE 乙酰胆碱 醋甲胆碱 卡巴胆碱 氯贝胆碱 AChE resistant ACh Derivatives Bethanechol 氯贝胆碱is most commonly used, particularly post-op for the treatment of paralytic ileus and urinary retention Natural Muscarinic Agonists 槟榔碱 毛果芸香碱 毒蕈碱 Nicotinic potency • Arecoline: areca or betal nuts (India,E. Indies) • Pilocarpine: pilocarpus (S. Amer. shrub) • Muscarine: amanita muscaria (mushroom) “Food” Poisoning • Poisoning causes muscarinic overstimulation: - salivation, lacrimation, visual disturbances; Amanita muscaria - abdominal colic and diarrhea 伞形毒蕈 - bronchospasm and bradycardia - hypotension; shock • Atropa belladonna 颠茄 Treatment is with atropine Pilocarpine (1) Eyes • Miosis (缩瞳): contraction of sphincter muscle of iris • Lowing intraocular pressure: enlarging angle of anterior chamber, increasing drainage of aqueous humor • Spasm of accommodation (调节痉挛): contraction of ciliary muscle, contraction for near vision • Ophthalmological 眼科 uses Glaucoma 青光眼: narrow (closed)- or wide (open)-angles used for the emergency lowering of intraocular pressure Iritis: miotics缩瞳药/mydriatics扩瞳药 Ciliary muscle (dilation) Canal of Schlemm mydriasis zonule Posterior chamber Anterior chamber lens iris paralysis of accommodation far sight atropine spasm of accommodation miosis zonule Anterior chamber Ciliary muscle (contraction) near sight pilocarpine Circulation of aqueous humor Glaucoma • Open-angle glaucoma: disease of the aging eye increased intraocular pressure, degeneration of the optic head, and restricted visual field • Obstruction of the aqueous drainage leads to elevated intraocular pressure (IOP), and may result in glaucomatous damage to the optic nerve Glaucoma • Glaucoma management involves lowering IOP by - Decreasing aqueous production by the ciliary body - Increasing aqueous outflow through the trabecular meshwork and uveal outflow paths • Pilocarpine: increase aqueous outflow by contraction of the ciliary muscle to increase tone and alignment of the trabecular network Pilocarpine (2) Promoting secretion of exocrine glands, especially in sweat, salivary and tear glands • Systemic use Antidote解毒剂 for atropine poisoning • Adverse effects M-like syndrome N receptor agonists: Nicotine Actions at ganglia, NMJ, brain are complex and frequently unpredictable, because of the variety of neuroeffector sites and because nicotine both stimulates and desensitizes effectors. Periphery: HR, BP, GI tone & motility CNS: stimulation, tremors, respiration, emetic effects The addictive power of cigarettes is directly related to their nicotine content. Drug classification 1. Cholinomimetics (1) Direct-acting drugs: Cholinoceptor agonists M, N receptor agonists: acetylcholine M receptor agonists: pilocarpine N receptor agonists: nicotine (2) Indirect-acting drugs: Cholinesterase inhibitors (Anticholinesterases) Reversible: neostigmine 新斯的明 Irreversible: organophosphates 有机磷酸酯类 Cholinesterase reactivators: pralidoxime iodide 碘解磷定 Acetylcholinesterase (AChE) Activity AChE Inhibitors A. Competitive (reversible) B. Carbamates (氨甲酰类slowly reversible) C. Organophosphates (irreversible) 依酚氯铵 These agents are reversible and are used medically (glaucoma or MG) 新斯的明 neostigmine 毒扁豆碱 These agents are irreversible and are used as pesticides or for glaucoma Acetylcholinesterase Inhibitors: Reversible Edrophonium (依酚氯铵) Rapidly absorbed; A short duration of action (5-15min); Competitive (reversible) Used in diagnosis of myasthenia gravis. Excess drug may provoke a cholinergic crisis, atropine is the antidote. Other reversible ACHEI: tacrine 他克林, donepezil 多奈哌齐 Acetylcholinesterase Inhibitors: Carbamates Inhibitory Effects are slowly reversible Representative Drugs neostigmine (quaternary amine 季铵) pyridostigmine (quaternary amine) physiostigmine (tertiary amine 叔胺) quaternary amines effective in periphery only tertiary amines effective in periphery and CNS (fat-soluble) Neostigmine 新斯的明 Pharmacological effects • AChE(-), ACh release↑, stimulating NMR • stronger effect on skeletal muscles • effective on GI tract and urinary bladder • more polar and can not enter CNS • relatively ineffective on CVS, glands, eye Neostigmine Clinical uses 1. Myasthenia gravis: symptomatic treatment overdose: cholinergic crisis 胆碱能危象:大量出汗,大小便失禁,瞳孔缩小,睫状肌痉挛, 心动过缓,低血压,肌无力,呼吸困难 2. Paralytic ileus 麻痹性肠梗阻urinary retention: post operative abdominal distension and urinary retention 3. Paroxysmal superventricular tachycardia(rarely use) 4. Antidote for tubocurarine ( 筒 箭 毒 碱 ) and related drug poisoning 5. Glaucoma Neostigmine Adverse effects • Cholinergic effects: muscarinic and nicotinic effects, treated with atropine (muscarinic) • Contraindications: mechanical ileus(机械性肠梗阻) urinary obstruction bronchial asthma poisoning of depolarizing skeletal muscle relaxants (e.g. succinylcholine, 琥珀酰胆碱) Acetylcholinesterase Inhibitors: Irreversible Bond is hydrolyzed in binding to the enzyme 乙磷硫胆碱 For ophthalmic use 梭曼 Dichlorvos 敌敌畏 对硫磷 对氧磷 Dimethoate 乐果 马拉硫磷 马拉氧磷 Organophosphates (1) Toxic symptoms Acute intoxication • Muscarinic symptom: eye, exocrine glands, respiration, GI tract, urinary tract, CVS • Nicotinic symptoms: NN: elevation of BP, increase of HR; NM: tremor of skeletal muscles • CNS symptoms: excitation, convulsion; depression (advanced phase) CASE STUDY • In mid-afternoon, a coworker brings 43-year-old JM to the emergency department because he is unable to continue picking vegetables. His gait is unsteady and he walks with support from his colleague. JM has difficulty speaking and swallowing, his vision is blurred, and his eyes are filled with tears. His coworker notes that JM was working in a field that had been sprayed early in the morning with a material that had the odor of sulfur. Within 3 hours after starting his work, JM complained of tightness in his chest that made breathing difficult, and he called for help before becoming disoriented. Organophosphates (1) Toxic symptoms Chronic intoxication • usually occupational poisoning • plasma ChE activity ↓, • weakness, restlessness, anxiety, tremor, miosis, …… Organophosphates (2) Detoxication • Elimination of poison; Supportive therapy • Antidotes Atropine-antagonizing muscarinic effects; early, large dose, and repeated use Cholinesterase reactivators-reactivation of phosphated AChE; moderate-severe patients, early use (More effective on tremor), combined with atropine – Pyraloxime methoiodide (PAM,碘解磷定) – Pralidoxime chloride (氯解磷定): safer than PAM – Obidoxime chloride(双复磷): two active oxime groups Organophosphates Pralidoxime (解磷 定)can restore AChE activity if administered soon after toxin exposure. • Conjugating with organophosphate by oxime group; • Conjugating with free organophasphates Why isn’t this ACHEI pesticide neurotoxic to humans? Malathion马拉硫磷 Insects and mammals metabolize the ‘prodrug’ differently Insects - P450 metabolism: P-S bond converted to P-O bond: now, the molecule, malaoxon, is an active inhibitor Mammals – esterase activity: hydrolyzes the molecule into inactive metabolites Summary: ACHEI Applications Pharmacological Actions: Increases ACh concentrations at cholinergic synapses, thereby increasing cholinergic activity. glaucoma (e.g. physiostigmine毒扁豆碱, echothiophate乙磷硫胆碱 ) myasthenia gravis (e.g. Edrophonium, neostigmine, pyridostigmine ) reverse neuromuscular blockade from competitive antagonists (neostigmine) Alzheimer’s disease (tacrine & donepezil, galanthamine) chemical warfare agents insecticides Drug classification 2 Cholinergic antagonists (1) Cholinoceptor antagonists • M cholinoceptor antagonists – atropine (Antimuscarinic drugs) • N cholinoceptor antagonists – NN cholinoceptor antagonists: mecamylamine (Ganglionic blocking drugs, rarely used) – NM cholinoceptor antagonists: succinylcholine (Neuromuscular blocking drugs ) • Botulinum Toxin (botox, blocks ACh release) Muscarinic Antagonists (Antimuscarinic drugs) Tertiary amines(叔铵) Quaternary amines(季铵) 东莨菪碱 异丙托铵 噻托溴铵 Atropa belladonna 颠茄 Datura sp. 洋金花 Datura stramonium 曼陀罗 Henbane Seed 山莨菪 Atropine 1. Pharmacological effects (1) Inhibition of exocrine gland secretion salivary, sweat glands tear, respiratory tract glands relatively ineffective: GI tract (2) Eye mydriasis 瞳孔散大 rise in intraocular pressure paralysis of accommodation调节麻痹 Ciliary muscle (dilation) Canal of Schlemm mydriasis zonule Posterior chamber Anterior chamber lens iris paralysis of accommodation far sight atropine miosis spasm of accommodation zonule Anterior chamber Ciliary muscle (contraction) near sight pilocarpine Atropine 1. Pharmacological effects (3) Antispasmodic action on smooth muscle • sensitive: GI, urinary bladder (spasmodic state) • relatively insensitive: bile duct, urinary tract, bronchial tract • insensitive: uterus Atropine 1. Pharmacological effects (4) Cardiovascular system: dose dependent • • • Lower therapeutic doses: HR↓(bradycardia); Blood vessels and blood pressure: no effect Moderate to high therapeutic doses / high vagal tone: HR↑ (tachycardia); A-V conduction ↑ Larger doses: cutaneous vasodilatation (5) CNS stimulation: • sedation, memory loss, psychosis (high dose) Atropine 2. Clinical uses (1) Ophthalmology Measurement of the refractive errors (屈光不正): children Acute iritis or iridocyclitis: mydriatics/miotics (2) Antispasmodic agent GI, biliary or renal colic, enuresis (3) Inhibiting exocrine gland secretion Preanesthetic medication麻醉前用药 (4) Bradycardia sinus or nodal bradycardia, A-V block (5) Antidote for organophosphate poisoning (6) Septic shock 感染性休克 Atropine 3. Adverse effects (1) Side effects dry mouth, blurred vision, “sandy eyes” (2) toxicity Lethal dose: 80~130 mg (adult), 10 mg (child) • Low: xerostomia (dry mouth); anhidrosis (dry skin), tachycardia • Moderate: above plus mydriasis, cycloplegia (睫状肌麻 痹); difficulty speaking, swallowing & urinating; and hot, red, dry skin • High: above plus ataxia, hallucinations幻觉 & delirium 谵妄; coma Atropine 3. Adverse effects (3) Detoxication Supportive treatment Symptomatic treatment: e.g. diazepam symptoms. Antidote: Physostigmine or pilocarpine (4) Contraindications glaucoma, prostatauxe 前列腺肥大, fever for CNS Scopolamine东莨菪碱 • Actions and clinical uses – Peripheral effects are similar to atropine; but has stronger central effects (depression) – Pre-anesthetic medication, prevention of motion sickness, Parkinson’s disease Anisodamine (654-1,2) • Actions and clinical uses – Peripheral effects, similar to atropine; lower toxicity – Septic shock and visceral colic (relieve spasm of vascular smooth muscles) Synthesized surrogates • Tropicamide 托吡卡胺: mydriatic, cycloplegic shorter duration (1/4 day) • Propantheline 丙胺太林,普鲁本辛 poor absorption (po) and BBB penetration • • • • antispasmodic effects in GI, treatment of peptic ulcer Ipratropium 异丙托铵: asthma Benztropine 苯托品: Parkinson’s disease Trihexyphenidyl 苯海索 Pirenzepine 哌仑西平:M1 selective, peptic ulcer, asthma CASE STUDY JH, a 63-year-old architect, complains of urinary symptoms to his family physician. He has hypertension and the last 8 years, he has been adequately managed with a thiazide diuretic and an angiotensin-converting enzyme inhibitor. During the same period, JH developed the signs of benign prostatic hypertrophy, which eventually required prostatectomy to relieve symptoms. He now complains that he has an increased urge to urinate as well as urinary frequency, and this has disrupted the pattern of his daily life. What do you suspect is the cause of JH’s problem? What information would you gather to confirm your diagnosis? What treatment steps would you initiate? Nicotinic receptor antagonists NN receptor antagonists (Ganglionic blocking drugs) • Acting on sympathetic and parasympathetic ganglionic cells; reducing blood pressure by inhibiting sympathetic ganglia ( have been abandoned for clinical use, due to their lack of selectivity) • Short-acting; tachyphylaxis (快速抗药反应) • Used for treatment of hypertension ─ Trimethaphan(咪噻芬) – Mecamylamine (美加明) NM receptor antagonists (Neuromuscular blocking drugs ) • Two classes: Depolarizing: succinylcholine 琥珀酰胆碱 Non-depolarizing: drugs act as competitive antagonists d-tubocurarine 筒箭毒碱 Note: Belong to Skeletal Muscle Relaxants. It is important to realize that muscle relaxation does not ensure unconsciousness, amnesia, or analgesia. NM receptor antagonists (Neuromuscular blocking drugs ) 1. Depolarizing neuromuscular blockers (Non-competitive) (depolarizing skeletal muscle relaxants) act as acetylcholine (ACh) receptor agonists the depolarized membranes remain depolarized and unresponsive to subsequent impulses (ie, they are in a state of depolarizing block). not metabolized by AChE - diffuse away from the neuromuscular junction and are hydrolyzed in the plasma and liver by pseudocholinesterase (nonspecific cholinesterase, plasma cholinesterase, or butyrylcholinesterase) and elimination by kidney Succinylcholine (Scoline司可林) acetylcholine succinylcholine Succinylcholine is the only depolarizing agent used clinically (t1/2= 2-4 min). Properties of actions: • • • • • • initially transient fasciculations (肌束震颤) anti-AChE potentiates their effects tachyphylaxis after repeated uses no ganglion-blocking effects at therapeutic doses the drugs are highly polar, poor bioavailability; i.v. as quaternary compounds, do not enter CNS Succinylcholine (Scoline) • Main pharmacological effects – Transient excitation (fasciculations), and then inhibition (relaxation) – Relax Skeletal Muscles in neck, limbs > face, tongue, throat; less effective on breath muscles at therapeutic doses Succinylcholine (Scoline) • Clinical uses – An adjuvant in anesthesia or operation – Intubation of trachea, esophagus, etc. – Prevention of trauma during electroshock therapy (无抽 搐电休克疗法) – Contraindicated in awake patients, should use under anesthesia Succinylcholine (Scoline) • Adverse effects (1) Apnea (respiratory paralysis) overdose or hypersensitive patients; neostigmine potentiates the toxic effects (2) Muscle spasm muscular pain after operation Succinylcholine (Scoline) (3) Elevation of K+ in plasma contraindicated in patients with a tendency of hyperkalemia (4) Malignant hyperthermia genetic abnormality, treated by dantrolene (Ca2+ release inhibitor) (5) Others rise in intraocular pressure (glaucoma); histamine release Genetic Variation: Effects on Duration of Action of Succinylcholine • Duration of action is prolonged by high doses or by abnormal metabolism. The latter may result from hypothermia (decreases the rate of hydrolysis), low pseudocholinesterase levels, or a genetically aberrant enzyme. • Low pseudocholinesterase levels generally produce only modest prolongation of succinylcholine's actions (2-20 min). • One in 50 patients has one normal and one abnormal (atypical) pseudocholinesterase gene, resulting in a slightly prolonged block (20-30 min). • Even fewer (1 in 3000) patients have two abnormal genes (homozygous atypical) that produce an enzyme with little or no affinity for succinylcholine and have a very long blockade (e.g., 4-8 h) following administration of succinylcholine. • Scoline apnea Succinylcholine (Scoline) • Drug interactions - Thiopental (强碱性,可分解scoline) - ChE inhibitors: AChE inhibitors, cyclophosphamide, procaine, etc. - Some antibiotics: kanamycin, polymyxins, etc. (synergism in neuromuscular blocking) NM receptor antagonists (Neuromuscular blocking drugs) 2. Nondepolarizing neuromuscular blockers (Competitive) (nondepolarizing skeletal muscle relaxants) Tubocurarine (筒箭毒碱) Reversibly bind to the nicotinic receptor at the neuromuscular junction (competitive antagonists) Tubocurarine • Effects: competitive blockade of NM receptors • Uses: adjuvant medication for anesthesia or operations, eg. tracheal intubation • Adverse effects: Respiratory paralysis: can be reversed by neostigmine Enhancing histamine release: BP , bronchoconstriction, salivary secretion Blocking ganglion: BP Contraindications: myasthenia gravis, bronchial asthma, shock, child (< 10 y) Other nondepolarizing neuromuscular blockers • Benzylisoquinolines(苄基异喹啉类) atracurium (阿曲库铵) doxacurium(多撒库铵) mivacurium(米库铵) • Ammonio steroids(类固醇铵类) pancuronium (潘库铵) vecuronium(维库铵) pipecuronium(哌库铵) rocuronium(罗库铵) Botulinum Toxin 肉毒杆菌毒素 - Skeletal muscle relaxants - blocks ACh release from cholinergic terminals - selective for ACh terminals - results in irreversible flaccid paralysis (松弛性瘫痪) in muscles Acts by cleaving SNAP proteins → inhibits ACh release Botulinum Toxin - an anaerobic bacillus, clostridium botulinum can multiply in preserved food - it synthesizes a protein that can be absorbed (pinocytosis or transport?) from the GI tract to reach the systemic circulation - penetrates tissues to reach cholinergic nerve terminals - then, it is uptaken (pinocytosis) and internalized in vesicles whose lumen becomes acidified - the low pH of the vesicles splits the inactive molecule into 2 active enzymes that have proteolysis functions Botulinum Toxin Applications • Strabismus (lack of parallelism of eyes 斜视), blepharospasm (eyelid spasm), dystonia (abnormal tonicity). • Excessive sweating • Cosmetic procedures ( “frown lines” or “crow’s feet”鱼尾纹) Note: effects can last for ~3-6 months. 参考书目 • 杨世杰主编《药理学》人民卫生出版社2010 第二版 • Katzung BG, Basic & Clinical Pharmacology (10th edition), 2007. • Lipincott’s illustrated reviews— Pharmocology (2nd edition), 2002